Jeannie Oliphant1, Joanna Stewart2, Peter Saxton3, Min Lo4, Nicky Perkins1, Daniel Ward5. 1. Auckland Sexual Health Service, Greenlane Clinical Centre, Auckland. 2. School of Population Health, University of Auckland, Auckland. 3. Social and Community Health, University of Auckland, Auckland. 4. Sexual Health, Private Practice, Auckland. 5. Foundation Year Two Doctor, Taunton and Somerset Foundation Trust, UK.
Abstract
AIM: To investigate whether changes in rates of genital warts diagnosis at Auckland Sexual Health Service (ASHS), pre and post the quadrivalent human papillomavirus (4vHPV) vaccine introduction in late 2008, differed between clients vaccine-eligible and not eligible. METHOD: All new clients attending ASHS from 2007 to 2013 were categorised as having genital warts or not. Generalised linear mixed models were used to compare differences in rates of change in diagnoses. RESULTS: Overall, 43,480 were seen with genital warts diagnosed in 13.1%. The difference in rate of change over time in diagnosis pre- to post-vaccine differed in females vaccine-eligible to not (p=0.004). The relative risk of diagnosis per year pre-vaccine was 0.98 (0.84, 1.13) and post-vaccine 0.77 (0.74, 0.81) in those eligible compared to 0.87 (0.80, 0.95) and 0.95 (0.91, 0.98), respectively, in those not eligible. This difference in change, between vaccine eligible or not, differed between males and females (p=0.02), with males considered eligible if the same aged female would have been. In males, no difference in rate change pre- to post-vaccine could be shown in those eligible or not (p=0.53). CONCLUSION: In this study a population effect for women of the 4vHPV vaccine was demonstrated.
AIM: To investigate whether changes in rates of genital warts diagnosis at Auckland Sexual Health Service (ASHS), pre and post the quadrivalent human papillomavirus (4vHPV) vaccine introduction in late 2008, differed between clients vaccine-eligible and not eligible. METHOD: All new clients attending ASHS from 2007 to 2013 were categorised as having genital warts or not. Generalised linear mixed models were used to compare differences in rates of change in diagnoses. RESULTS: Overall, 43,480 were seen with genital warts diagnosed in 13.1%. The difference in rate of change over time in diagnosis pre- to post-vaccine differed in females vaccine-eligible to not (p=0.004). The relative risk of diagnosis per year pre-vaccine was 0.98 (0.84, 1.13) and post-vaccine 0.77 (0.74, 0.81) in those eligible compared to 0.87 (0.80, 0.95) and 0.95 (0.91, 0.98), respectively, in those not eligible. This difference in change, between vaccine eligible or not, differed between males and females (p=0.02), with males considered eligible if the same aged female would have been. In males, no difference in rate change pre- to post-vaccine could be shown in those eligible or not (p=0.53). CONCLUSION: In this study a population effect for women of the 4vHPV vaccine was demonstrated.
Authors: Anita Lukács; Zsuzsanna Máté; Nelli Farkas; Alexandra Mikó; Judit Tenk; Péter Hegyi; Balázs Németh; László Márk Czumbel; Sadaeng Wuttapon; István Kiss; Zoltán Gyöngyi; Gábor Varga; Zoltán Rumbus; Andrea Szabó Journal: BMC Public Health Date: 2020-05-28 Impact factor: 3.295